Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes
- Conditions
- Interventions
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 9
- Registration Number
- NCT01746875
- Locations
- 🇳🇴
Department of Neuroscience, NTNU, Trondheim, Norway
Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment
- Conditions
- Interventions
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2016-01-22
- Target Recruit Count
- 40
- Registration Number
- NCT01722656
- Locations
- 🇺🇸
Jules Stein Eye Institute, Los Angeles, California, United States
🇺🇸Southern California Desert Retina Consultants, Palm Desert, California, United States
🇺🇸Black Hills Regional Eye Institute, Rapid City, South Dakota, United States
Use of Eylea for the Treatment of an Optic Nerve Hemangioma
- Conditions
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Vitreous -Retina- Macula Consultants of New York
- Registration Number
- NCT01714115
- Locations
- 🇺🇸
Vitreous Retina Macula Consultants of New York, New York, New York, United States
Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 7
- Registration Number
- NCT01711879
- Locations
- 🇺🇸
Rocky Mountain Lions Eye Institute, Aurora, Colorado, United States
Colorectal Cancer Metastatic
- Conditions
- Interventions
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 175
- Registration Number
- NCT01670721
- Locations
- 🇫🇷
Administrative office, Paris, France
Adjuvant Aflibercept for Metastatic Colorectal Cancer
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Brown University
- Target Recruit Count
- 10
- Registration Number
- NCT01669720
- Locations
- 🇺🇸
Rhode Island Hospital (East Greenwich and Newport), Providence, Rhode Island, United States
🇺🇸The Miriam Hospital, Providence, Rhode Island, United States
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Tennessee Retina
- Target Recruit Count
- 30
- Registration Number
- NCT01670162
- Locations
- 🇺🇸
Pacific Eye Associates, San Fransisco, California, United States
🇺🇸Retina Associates of Kentucky, Lexington, Kentucky, United States
🇺🇸Tennessee Retina, P.C., Nashville, Tennessee, United States
A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 332
- Registration Number
- NCT01661270
- Locations
- 🇨🇳
Investigational Site Number 156001, Beijing, China
🇨🇳Investigational Site Number 156003, Beijing, China
🇨🇳Investigational Site Number 156016, Chengdu, China
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Rishi Singh
- Target Recruit Count
- 26
- Registration Number
- NCT01617148
- Locations
- 🇺🇸
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Vitreous -Retina- Macula Consultants of New York
- Registration Number
- NCT01495208
- Locations
- 🇺🇸
Vitreous Retina Macula Consultants of New York, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.